Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla malesuada lectus tortor, non mattis metus dictum sed. Vestibulum tincidunt at lectus eget finibus. Morbi vel mauris porttitor, laoreet lacus in, porttitor urna. Pellentesque porttitor malesuada eleifend. Fusce maximus diam auctor tellus congue interdum. Vivamus aliquet orci et orci aliquam rutrum. Aenean ut congue sem. Fusce lorem nulla, eleifend ac varius vel, lobortis a nibh.
Washington, D.C. (March 31, 2016)— Today, The ALS Association is pleased to announce the awarding of an ALS Association-Initiated Grant to David Ennist, Ph.D., M.B.A, Chief Scientific Officer of Origent Data Sciences, Inc. based in Vienna, VA for $497,433 over 34 months that will enable a research partnership with Cytokinetics Inc. (Nasdaq: CYTK) to improve clinical trial design. The topic of Dr. Ennist’s project is “Prospective Validation of ALS Disease Models and Tools.” This collaboration will refine and prospectively validate an Origent computer model to predict the course of ALS disease progression leveraging data from Cytokinetics’ clinical trials of tirasemtiv, the first of its kind in a clinical trial setting.
Donec rutrum congue leo eget malesuada. Curabitur aliquet quam id dui posuere blandit. Vivamus magna justo, lacinia eget consectetur sed, convallis at tellus. Cras ultricies ligula sed magna dictum porta. Curabitur aliquet quam id dui posuere blandit. Proin eget tortor risus. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed porttitor lectus nibh. Vivamus suscipit tortor eget felis porttitor volutpat. Donec rutrum congue leo eget malesuada.
Curabitur aliquet quam id dui posuere blandit. Vivamus magna justo, lacinia eget consectetur sed, convallis at tellus. Cras ultricies ligula sed magna dictum porta. Curabitur aliquet quam id dui posuere blandit. Proin eget tortor risus. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed porttitor lectus nibh. Vivamus suscipit tortor eget felis porttitor volutpat. Donec rutrum congue leo eget malesuada.
Recent Comments